StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Teva Pharma (TEVA) Leaving Room for Upside Surprise in EBITDA Guidance - Evercore ISI
February 8, 2018 8:32 AM
Evercore ISI analyt Umer Raffat said Teva Pharma (NYSE: TEVA) EBITDA expectations at $4.7-$5B (vs sell ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS View
Trader Talk
Next Articles
Teva Pharma (TEVA) PT Lowered to $23 at Goldman Sachs; Remains Bullish as Expectations Reset
February 9, 2018 8:52 AM
Teva Pharma (TEVA) PT Lowered to $16.50 at Wells Fargo
February 9, 2018 8:05 AM
Teva Pharma (TEVA) PT Lowered to $16 at Cowen
February 8, 2018 12:37 PM
Teva Pharma (TEVA) Tops Q4 EPS by 17c, FY18 Guidance Falls Short of Views
February 8, 2018 7:05 AM
Teva Reports 2017 Full Year and Fourth Quarter Financial Results
February 8, 2018 7:01 AM
